<2>Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
<3>The Danish pharmaceutical giant’s shares dropped on Monday as a head-to-head study revealed that its experimental drug, semaglutide, failed to outperform Eli Lilly’s existing weight-loss medication, Mounjaro, in cutting body weight.
<4>According to a report by < href='https://bloomberg.com' target='_blank'>Bloomberg, the study, which was conducted by Novo Nordisk, found that patients taking semaglutide lost an average of 5.3% of their body weight over a 20-week period, compared to 7.1% for those taking Mounjaro.
<5>The disappointing results of the study sent Novo Nordisk’s shares plummeting, with the company’s stock price falling by as much as 10% in early trading on Monday.
<6>Analysts had been expecting semaglutide to outperform Mounjaro, which has been a major player in the weight-loss market since its approval in 2022. However, the study’s findings suggest that Mounjaro may be a more effective treatment for weight loss than previously thought.
<7>Nov